Infection
Conditions
Keywords
antibiotic prescription, infections, decision tree, point-of-care C-reactive protein test, safetynet advice
Brief summary
Impact of clinical guidance & point-of-care CRP test in children: the ARON project Trial Design: multicentre, cluster-randomized, parallel group pragmatic trial Trial Participants and setting: Children aged 6 months to 12 years of age with an acute illness episode presenting to in-hours general practice or out-of-hospital community paediatrics offices Intervention(s) Diagnostic algorithm: 1. Clinical decision tree: clinician's gut feeling something is wrong, dyspnea, temperature ≥40ºC 2. YES to any : point-of-care CRP ≥5mg/L: additional testing or refer to secondary care \<5mg/L: safety netting\*, only prescribe antibiotics if advised (guidelines) 3. NO to all : are AB considered? YES : point-of-care CRP ≥5mg/L: safety netting\*, only prescribe antibiotics if advised (guidelines) \<5mg/L: safety netting\*, do not prescribe antibiotics NO: safety netting \*safety netting advice: * inform parents on what to expect and what to look out for * interactive parent information booklet based on previous research Control: Diagnosis and Treatment/Management as per usual care: \- guidance on AB prescribing: o Belgische Commissie voor de Coördinatie van het Antibioticabeleid (BAPCOC) guide (updated November 2019) o RIZIV consensus meeting report Antibiotics in children in ambulatory care Primary Endpoint: Antibiotic prescribing rate at index consultation Secondary Endpoint(s) \- time until full clinical recovery (during follow up (day 1 to day 30)) \- additional investigations (at index consultation and/or during follow up (day 1 to day 30)) \- re-consultation (during follow up (day 1 to day 30)) \- antibiotic prescribing rate (during follow up (day 1 to day 30)) Exploratory endpoints at the index consultation: * additional investigations (X-Ray, blood tests, urine tests, etc.) During a follow-up period (day 1 to day 30): \- referral to hospital \- additional investigations (X-Ray, blood tests, urine tests, etc.) * patients with full clinical recovery at day 7 and day 30 * admission to hospital * mortality * cost-effectiveness * patient satisfaction * qualitative study: endpoints Planned Sample Size: 7000 Timing of the intervention: Intervention at index consultation (at presentation to primary care) Follow-up duration: 30 days follow-up Duration of the trial (FPI-CSR): 43 months
Detailed description
The investigators aim to strengthen the assessment of acutely ill children in primary care, by introducing a diagnostic algorithm that can decrease antibiotic prescribing. In light of the prior evidence and its results so far, the ARON trial will test the impact of a diagnostic algorithm including a standardised clinical assessment, a POC CRP test, and safety netting advice. Therefore, the investigators propose to assess the clinical and cost-effectiveness of a diagnostic algorithm which includes a decision tree, POC CRP and safety netting advice in acutely ill children aged 6 months to 12 years of age presenting to ambulatory care, on AB prescribing, referral/admission to hospital, additional testing, mortality, and patient satisfaction. More specifically, the investigators' research question is whether this diagnostic algorithm is able to safely reduce antibiotic prescribing in acutely ill children presenting to ambulatory care. The decision whether or not to conduct a POC CRP test will depend on the standardized clinical assessment, i.e. a validated clinical decision tree, and subsequently for low-risk children on the intention to prescribe AB. The investigators will provide clear evidence-based guidance on how to interpret the CRP test result as outlined below. A process evaluation will examine how clinicians use CRP testing in their practice and how parents experience these consultations. The investigators propose a study, where children (6 months to 12 years of age) will be randomised to (a) a diagnostic algorithm with CRP testing and specific guidance on when to prescribe AB or (b) usual care. CRP testing will be done using a finger prick test (result within 4 minutes). The CRP level will then be given to the clinician who will communicate the result to the child/parents. The investigators aim to recruit 7000 children and will collect data registered by the participating physician, from the child's health record and children/parents directly. The investigators will describe how the intervention has worked in practice and how clinicians/parents have experienced these consultations. Guidance will be part of a diagnostic algorithm which includes clinically guided POC CRP testing and safety netting advice to inform parents on what to expect and what to look out for. Individual interviews will be conducted with clinicians and parents taking part in the trial within 30 days after the first contact consultation, to explore the social processes influencing embedding of the intervention within practice, and behaviour change techniques. These individual telephone interviews will be performed with a selection of parents to address whether their concerns were discussed appropriately and whether their expectations were met and how they experienced the consultation and/or POC CRP testing. The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor)). The findings of this study could change the practice of ambulatory care physicians and might be of great interest to parents and childcare providers. The investigators will publish the findings of this research in academic journals, present at national conferences and discuss results with groups responsible for the national guidance on how to assess acutely ill children (Domus Medica, SSMG).
Interventions
Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea). The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor)).
Sponsors
Study design
Masking description
Owing to study procedures, children, their parents and physicians will not be masked to the practices' random allocation.
Intervention model description
multicentre, cluster-randomized, parallel group pragmatic trial
Eligibility
Inclusion criteria
for practices: * Being able to recruit acutely ill children (ideally consecutively) * Agree to the terms of the clinical study agreement.
Exclusion criteria
for practices: * Currently using a POC CRP device as part of their routine care * No practices will be excluded on other grounds than the above. Age, demographics, geographic region will not be used to exclude eligible practices. This will provide us with a real-life, representative subset of ambulatory care physicians. Inclusion criteria for children * Children aged 6 months to 12 years, provided informed consent can be obtained * presenting with an acute illness episode that started maximum 10 days before the index consultation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed) | This outcome will be registered immediately at the index consultation (immediately after the intervention) | The primary outcome is the percentage of participants who were prescribed antibiotic treatment (both immediate and delayed) at the index consultation as recorded by the treating physician. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical Recovery During Follow-up | This outcome will be checked from the diary (via app for parents) from first day after the intervention until day of full clinical recovery (up to maximum 30 days after after the intervention) | the duration (in days) until reaching full clinical recovery |
| Additional Investigations at Index Consultation and/or During Follow-up | This composite outcome will be registered immediately after the intervention and/or checked from the patient health record from the first day to day 30 after the intervention | the percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) and/or during follow-up (day 1 to day 30) |
| Re-consultation During Follow-up | This outcome will be checked from the patient health record from first day to day 30 after the intervention | percentage of subjects who re-consulted their physician during follow-up (day 1 to day 30) |
| Antibiotic Prescribing Rate During Follow-up | This outcome will be checked from the patient health record first day to day 30 after the intervention | percentage of subjects who were prescribed antibiotic treatment during follow-up (day 1 to day 30) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Admission to Hospital During Follow-up | during follow-up from first day to day 30 after the intervention | percentage of subjects admitted to hospital during follow-up (day 1 to day 30) |
| Mortality at Day 0 | This outcome will be registered immediately at the index consultation | percentage of subjects who died at index consultation (day 0) |
| Mortality During Follow up | during follow-up from first day to day 30 after the intervention | percentage of subjects who died during follow-up (day 1 to day 30) |
| Clinical Recovery at Day 7 | at day 7 after the intervention | percentage of subjects with full clinical recovery at day 7 |
| Clinical Recovery at Day 30 | at day 30 after the intervention | percentage of subjects with full clinical recovery at day 30 |
| Additional Testing at Index Consultation | This outcome will be registered immediately at the index consultation | percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) |
| Parent's Experience Through Semi-structured Interviews | within 7 days after the intervention | Parent's experience through semi-structured interviews with pre-defined topic guide |
| Physician's Experience Through Semi-structured Interviews | within 7 days after the intervention | Physician's experience through semi-structured interviews with pre-defined topic guide |
| Cost-effectiveness of the Intervention | will be assessed retrospectively after data collection has finished (24 months of recruitment) | Cost-effectiveness of the intervention: healthcare expenditures in terms of hospitalization, consultations, pharmaceuticals (reimbursed and non-reimbursed), productivity, quality of life |
| Number of Participants Whose Physician Was Non-Adherent to the Diagnostic Algorithm | This outcome will be registered immediately at the index consultation | clinicians could deviate from the proposed diagnostic algorithm. This outcome measure comprise the percentage of participants whose physician was non-adherent to the diagnostic algorithm. This is not a protocol violation, since deviating from the algorithm was a possibility if the physician deems this necessary. |
| Patient's Experience Through Semi-structured Interviews | within 7 days after the intervention | Patient's experience through semi-structured interviews with pre-defined topic guide |
| Additional Testing During Follow-up | during follow-up from first day to day 30 after the intervention | percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) during follow-up (day 1 to day 30) |
| Referral to Hospital at Day 0 | This outcome will be registered immediately at the index consultation | percentage of subjects referred to hospital at index consultation (day 0) |
| Referral to Hospital During Follow-up | during follow-up from first day to day 30 after the intervention | percentage of subjects referred to hospital during follow-up (day 1 to day 30) |
| Admission to Hospital at Day 0 | This outcome will be registered immediately at the index consultation | percentage of subjects admitted to hospital at index consultation (day 0) |
Countries
Belgium
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Intervention: Diagnostic Algorithm diagnostic algorithm including a standardised clinical assessment, a Point-of-care C-reactive protein test, and safety netting advice
diagnostic algorithm: Guidance will be part of a diagnostic algorithm which includes clinically guided point-of-care C-reactive protein testing and safety netting advice to inform parents on what to expect and what to look out for. A selection of clinical features will be assessed and recorded by the physician in the patient's health record and on the e-CRF, including the clinical decision tree (clinician's gut feeling, body temperature, dyspnea).
The safety-netting advice will be supported by a parent information booklet, based on previous research (the When should I worry-interactive booklet (a guide to Coughs, Colds, Earache & Sore Throats), the Mijn kind heeft koorts booklet (Eefje de Bont, www.thuisarts.nl), and the Caring for children with coughs-leaflet (information about how to look after a child who has a cough and when to see the doctor)). | 2,988 |
| Usual Care In the control arm, patients will receive 'usual care' left at the discretion of the treating physician.
Apart from the general training session for all participating physicians they have attended prior to recruitment and randomization, physicians in the control arm will not receive additional tools.
They are expected (but not forced) to follow the Belgian guidelines (as described in BAPCOC National guidelines and the RIZIV consensus meeting Rational use of antibiotics in children). | 3,762 |
| Total | 6,750 |
Baseline characteristics
| Characteristic | Usual Care | Total | Intervention: Diagnostic Algorithm |
|---|---|---|---|
| Age, Continuous | 3.9 years | 3.75 years | 3.7 years |
| Race and Ethnicity Not Collected | — | 0 Participants | — |
| Region of Enrollment Belgium | 3762 participants | 6750 participants | 2988 participants |
| Sex/Gender, Customized boy | 1881 Participants | 3447 Participants | 1566 Participants |
| Sex/Gender, Customized girl | 1881 Participants | 3302 Participants | 1421 Participants |
| Sex/Gender, Customized prefer not to say | 0 Participants | 1 Participants | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 2,988 | 0 / 3,762 |
| other Total, other adverse events | 32 / 2,988 | 64 / 3,762 |
| serious Total, serious adverse events | 0 / 2,988 | 0 / 3,762 |
Outcome results
Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed)
The primary outcome is the percentage of participants who were prescribed antibiotic treatment (both immediate and delayed) at the index consultation as recorded by the treating physician.
Time frame: This outcome will be registered immediately at the index consultation (immediately after the intervention)
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed) | 466 Participants |
| Usual Care | Antibiotic Prescribing Rate at Index Consultation (Immediate or Delayed) | 817 Participants |
Additional Investigations at Index Consultation and/or During Follow-up
the percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0) and/or during follow-up (day 1 to day 30)
Time frame: This composite outcome will be registered immediately after the intervention and/or checked from the patient health record from the first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Additional Investigations at Index Consultation and/or During Follow-up | 335 Participants |
| Usual Care | Additional Investigations at Index Consultation and/or During Follow-up | 517 Participants |
Antibiotic Prescribing Rate During Follow-up
percentage of subjects who were prescribed antibiotic treatment during follow-up (day 1 to day 30)
Time frame: This outcome will be checked from the patient health record first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Antibiotic Prescribing Rate During Follow-up | 291 Participants |
| Usual Care | Antibiotic Prescribing Rate During Follow-up | 429 Participants |
Clinical Recovery During Follow-up
the duration (in days) until reaching full clinical recovery
Time frame: This outcome will be checked from the diary (via app for parents) from first day after the intervention until day of full clinical recovery (up to maximum 30 days after after the intervention)
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Intervention: Diagnostic Algorithm | Clinical Recovery During Follow-up | 4.6 days | Standard Deviation 3.5 |
| Usual Care | Clinical Recovery During Follow-up | 4.7 days | Standard Deviation 3.6 |
Re-consultation During Follow-up
percentage of subjects who re-consulted their physician during follow-up (day 1 to day 30)
Time frame: This outcome will be checked from the patient health record from first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Re-consultation During Follow-up | 770 Participants |
| Usual Care | Re-consultation During Follow-up | 968 Participants |
Additional Testing at Index Consultation
percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) at index consultation (day 0)
Time frame: This outcome will be registered immediately at the index consultation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Additional Testing at Index Consultation | 249 Participants |
| Usual Care | Additional Testing at Index Consultation | 400 Participants |
Additional Testing During Follow-up
percentage of subjects receiving additional testing (including, but not limited to (X-Ray, blood tests, urine tests) during follow-up (day 1 to day 30)
Time frame: during follow-up from first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Additional Testing During Follow-up | 111 Participants |
| Usual Care | Additional Testing During Follow-up | 149 Participants |
Admission to Hospital at Day 0
percentage of subjects admitted to hospital at index consultation (day 0)
Time frame: This outcome will be registered immediately at the index consultation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Admission to Hospital at Day 0 | 7 Participants |
| Usual Care | Admission to Hospital at Day 0 | 11 Participants |
Admission to Hospital During Follow-up
percentage of subjects admitted to hospital during follow-up (day 1 to day 30)
Time frame: during follow-up from first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Admission to Hospital During Follow-up | 25 Participants |
| Usual Care | Admission to Hospital During Follow-up | 53 Participants |
Clinical Recovery at Day 30
percentage of subjects with full clinical recovery at day 30
Time frame: at day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Clinical Recovery at Day 30 | 2967 Participants |
| Usual Care | Clinical Recovery at Day 30 | 3747 Participants |
Clinical Recovery at Day 7
percentage of subjects with full clinical recovery at day 7
Time frame: at day 7 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Clinical Recovery at Day 7 | 2539 Participants |
| Usual Care | Clinical Recovery at Day 7 | 3200 Participants |
Cost-effectiveness of the Intervention
Cost-effectiveness of the intervention: healthcare expenditures in terms of hospitalization, consultations, pharmaceuticals (reimbursed and non-reimbursed), productivity, quality of life
Time frame: will be assessed retrospectively after data collection has finished (24 months of recruitment)
Mortality at Day 0
percentage of subjects who died at index consultation (day 0)
Time frame: This outcome will be registered immediately at the index consultation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Mortality at Day 0 | 0 Participants |
| Usual Care | Mortality at Day 0 | 0 Participants |
Mortality During Follow up
percentage of subjects who died during follow-up (day 1 to day 30)
Time frame: during follow-up from first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Mortality During Follow up | 0 Participants |
| Usual Care | Mortality During Follow up | 0 Participants |
Number of Participants Whose Physician Was Non-Adherent to the Diagnostic Algorithm
clinicians could deviate from the proposed diagnostic algorithm. This outcome measure comprise the percentage of participants whose physician was non-adherent to the diagnostic algorithm. This is not a protocol violation, since deviating from the algorithm was a possibility if the physician deems this necessary.
Time frame: This outcome will be registered immediately at the index consultation
Population: missing data from 2 participants
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Number of Participants Whose Physician Was Non-Adherent to the Diagnostic Algorithm | 160 Participants |
Parent's Experience Through Semi-structured Interviews
Parent's experience through semi-structured interviews with pre-defined topic guide
Time frame: within 7 days after the intervention
Patient's Experience Through Semi-structured Interviews
Patient's experience through semi-structured interviews with pre-defined topic guide
Time frame: within 7 days after the intervention
Physician's Experience Through Semi-structured Interviews
Physician's experience through semi-structured interviews with pre-defined topic guide
Time frame: within 7 days after the intervention
Referral to Hospital at Day 0
percentage of subjects referred to hospital at index consultation (day 0)
Time frame: This outcome will be registered immediately at the index consultation
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Referral to Hospital at Day 0 | 24 Participants |
| Usual Care | Referral to Hospital at Day 0 | 13 Participants |
Referral to Hospital During Follow-up
percentage of subjects referred to hospital during follow-up (day 1 to day 30)
Time frame: during follow-up from first day to day 30 after the intervention
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Intervention: Diagnostic Algorithm | Referral to Hospital During Follow-up | 79 Participants |
| Usual Care | Referral to Hospital During Follow-up | 84 Participants |